A Study to Assess the Long-term Use of Alprazolam Extended Release (XL) in the Treatment of Adolescents With Panic Disorder

Stopped early · Phase 4 · Has a placebo group

Conditions studied: Panic Disorder

In brief

The purpose of this study is to evaluate the long-term (6-month) efficacy, safety, and tolerability of alprazolam XR in adolescents with panic disorder.

Key facts

Study ID
NCT00635076
Run by
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
People needed
3
Starts
2004-07-01
Expected to finish
2004-09-01
Last updated by the study team
2021-01-28

Who can join

Age: 13 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.